A phase I study of PARP inhibitor (niraparib) plus HSP90 inhibitor (pimitespib) in solid tumors: The NiraPim (EPOC2102) study
Latest Information Update: 13 Jan 2025
Price :
$35 *
At a glance
- Drugs Niraparib (Primary) ; Pimitespib (Primary)
- Indications Advanced breast cancer; Ovarian cancer; Solid tumours
- Focus Adverse reactions
- Acronyms nirapim study
- 09 Jan 2025 New trial record
- 17 Sep 2024 Trial design presented at the 49th European Society for Medical Oncology Congress
- 17 Sep 2024 According to Trial design presented at the 49th European Society for Medical Oncology Congress, dose-escalation part has been completed, the RD has been determined, and the dose-expansion part has commenced.